×

Transforming therapies with proprietary dermal delivery technology, so people with cancer live better, longer

Start a new standard

Starton Therapeutics is transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, longer.

Targeted continuous delivery

We transform FDA-approved medicines and leverage our dermal delivery systems to establish new profiles. Our platform technology allows for lower drug exposure and the potential for improved efficacy.

Careers

Building a team dedicated to delivering breakthrough, transformative products for patients with blood cancers.We offer comprehensive and competitive health, financial, paid time off and many other benefits designed to promote the health and well-being of our employees and their families.

News and Events

September 27, 2022

Starton Therapeutics Announces Appointment of Moses Dodo to Its Board of Directors

NEW YORK, N.Y., September 27, 2022 – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company powering continuous delivery of approved drugs in novel indications, announced…

August 18, 2022

Starton Therapeutics to Present Poster at International Myeloma Society Annual Meeting 2022

PARAMUS, N.J., AUGUST 18, 2022 – Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company today announced that the Company will present a poster at the International Myeloma…

XML 地图